Post by Drug Discovery News

Landos Biopharma, Inc. touts results of Phase 2 #ClinicalTrials of BT-11 vs mild-to-moderate #UlcerativeColitis See positive trend in clinical #remission rates with gut-restricted #LANCL2 modulator, consistent with standard of care https://lnkd.in/gvNsVjB #autoimmune #IBD #gastroenterology Solebury Trout